Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 439 entries
Sorted by: Best Match Show Resources per page
RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.

Case reports in oncology

Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA.
PMID: 26933418
Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. eCollection 2016.

We present the case of a 49-year-old male with metastatic epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma of the lung that continues to outlive stage IV diagnosis of non-small cell lung cancer after treatment with RRx-001, an experimental anticancer...

Cite
Brzezniak C, Schmitz BA, Peterson PG, et al. RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report. Case Rep Oncol. 2016;9(1):45-50doi: 10.1159/000443605.
Brzezniak, C., Schmitz, B. A., Peterson, P. G., Degesys, A., Oronsky, B. T., Scicinski, J. J., Caroen, S. Z., & Carter, C. A. (2016). RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report. Case reports in oncology, 9(1), 45-50. https://doi.org/10.1159/000443605
Brzezniak, Christina, et al. "RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report." Case reports in oncology vol. 9,1 (2016): 45-50. doi: https://doi.org/10.1159/000443605
Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA. RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report. Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. eCollection 2016. PMID: 26933418; PMCID: PMC4748757.
Copy Download .nbib Format: NLM
Intravenous zoledronate for osteoporosis: less might be more.

Therapeutic advances in musculoskeletal disease

Grey A.
PMID: 27493690
Ther Adv Musculoskelet Dis. 2016 Aug;8(4):119-23. doi: 10.1177/1759720X16650866. Epub 2016 May 19.

Annual administration of 5 mg intravenous zoledronate is moderately effective in reducing fracture risk in older adults, decreasing the relative risk of clinical fracture by 33%. However, almost 10 years after its approval for use in clinical practice there...

Cite
Grey A. Intravenous zoledronate for osteoporosis: less might be more. Ther Adv Musculoskelet Dis. 2016;8(4):119-23doi: 10.1177/1759720X16650866.
Grey, A. (2016). Intravenous zoledronate for osteoporosis: less might be more. Therapeutic advances in musculoskeletal disease, 8(4), 119-23. https://doi.org/10.1177/1759720X16650866
Grey, Andrew. "Intravenous zoledronate for osteoporosis: less might be more." Therapeutic advances in musculoskeletal disease vol. 8,4 (2016): 119-23. doi: https://doi.org/10.1177/1759720X16650866
Grey A. Intravenous zoledronate for osteoporosis: less might be more. Ther Adv Musculoskelet Dis. 2016 Aug;8(4):119-23. doi: 10.1177/1759720X16650866. Epub 2016 May 19. PMID: 27493690; PMCID: PMC4959627.
Copy Download .nbib Format: NLM
Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy.

PLoS currents

Rubinson L, Corey A, Hanfling D.
PMID: 28856066
PLoS Curr. 2017 Jul 28;9. doi: 10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d.

INTRODUCTION: Infrequent natural human inhalational anthrax cases coupled with high bioterrorism risk have brought about use of animal models to serve as the basis for approval of novel treatments. For inhalational anthrax, protective antigen (PA) drives much of the...

Cite
Rubinson L, Corey A, Hanfling D. Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy. PLoS Curr. 2017;9doi: 10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d.
Rubinson, L., Corey, A., & Hanfling, D. (2017). Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy. PLoS currents, 9. https://doi.org/10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d
Rubinson, Lewis, et al. "Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy." PLoS currents vol. 9 (2017). doi: https://doi.org/10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d
Rubinson L, Corey A, Hanfling D. Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy. PLoS Curr. 2017 Jul 28;9. doi: 10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d. PMID: 28856066; PMCID: PMC5555766.
Copy Download .nbib Format: NLM
Validation of a quantitative phosphorus loss assessment tool.

Journal of environmental quality

White MJ, Storm DE, Smolen MD, Busteed PR, Zhang H, Fox GA.
PMID: 25602555
J Environ Qual. 2014 Jan;43(1):224-34. doi: 10.2134/jeq2011.0434.

Pasture Phosphorus Management Plus (PPM Plus) is a tool that allows nutrient management and conservation planners to evaluate phosphorus (P) loss from agricultural fields. This tool uses a modified version of the widely used Soil and Water Assessment Tool...

Cite
White MJ, Storm DE, Smolen MD, et al. Validation of a quantitative phosphorus loss assessment tool. J Environ Qual. 2014;43(1):224-34doi: 10.2134/jeq2011.0434.
White, M. J., Storm, D. E., Smolen, M. D., Busteed, P. R., Zhang, H., & Fox, G. A. (2014). Validation of a quantitative phosphorus loss assessment tool. Journal of environmental quality, 43(1), 224-34. https://doi.org/10.2134/jeq2011.0434
White, Michael J, et al. "Validation of a quantitative phosphorus loss assessment tool." Journal of environmental quality vol. 43,1 (2014): 224-34. doi: https://doi.org/10.2134/jeq2011.0434
White MJ, Storm DE, Smolen MD, Busteed PR, Zhang H, Fox GA. Validation of a quantitative phosphorus loss assessment tool. J Environ Qual. 2014 Jan;43(1):224-34. doi: 10.2134/jeq2011.0434. PMID: 25602555.
Copy Download .nbib Format: NLM
Aerobic Capacity is Related to Repeated Sprint Ability with Sprint Distances Less Than 40 Meters.

International journal of exercise science

Sanders GJ, Turner Z, Boos B, Peacock CA, Peveler W, Lipping A.
PMID: 28344734
Int J Exerc Sci. 2017 Mar 01;10(2):197-204. eCollection 2017.

Research is inconclusive regarding the association between aerobic fitness (objectively measured VO

Cite
Sanders GJ, Turner Z, Boos B, et al. Aerobic Capacity is Related to Repeated Sprint Ability with Sprint Distances Less Than 40 Meters. Int J Exerc Sci. 2017;10(2):197-204
Sanders, G. J., Turner, Z., Boos, B., Peacock, C. A., Peveler, W., & Lipping, A. (2017). Aerobic Capacity is Related to Repeated Sprint Ability with Sprint Distances Less Than 40 Meters. International journal of exercise science, 10(2), 197-204.
Sanders, Gabriel J, et al. "Aerobic Capacity is Related to Repeated Sprint Ability with Sprint Distances Less Than 40 Meters." International journal of exercise science vol. 10,2 (2017): 197-204.
Sanders GJ, Turner Z, Boos B, Peacock CA, Peveler W, Lipping A. Aerobic Capacity is Related to Repeated Sprint Ability with Sprint Distances Less Than 40 Meters. Int J Exerc Sci. 2017 Mar 01;10(2):197-204. eCollection 2017. PMID: 28344734; PMCID: PMC5360375.
Copy Download .nbib Format: NLM
Layered Bi2Se3 nanoplate/polyvinylidene fluoride composite based n-type thermoelectric fabrics.

ACS applied materials & interfaces

Dun C, Hewitt CA, Huang H, Xu J, Montgomery DS, Nie W, Jiang Q, Carroll DL.
PMID: 25798653
ACS Appl Mater Interfaces. 2015 Apr 08;7(13):7054-9. doi: 10.1021/acsami.5b00514. Epub 2015 Mar 27.

In this study, we report the fabrication of n-type flexible thermoelectric fabrics using layered Bi2Se3 nanoplate/polyvinylidene fluoride (PVDF) composites as the thermoelectric material. These composites exhibit room temperature Seebeck coefficient and electrical conductivity values of -80 μV K(-1) and...

Cite
Dun C, Hewitt CA, Huang H, et al. Layered Bi2Se3 nanoplate/polyvinylidene fluoride composite based n-type thermoelectric fabrics. ACS Appl Mater Interfaces. 2015;7(13):7054-9doi: 10.1021/acsami.5b00514.
Dun, C., Hewitt, C. A., Huang, H., Xu, J., Montgomery, D. S., Nie, W., Jiang, Q., & Carroll, D. L. (2015). Layered Bi2Se3 nanoplate/polyvinylidene fluoride composite based n-type thermoelectric fabrics. ACS applied materials & interfaces, 7(13), 7054-9. https://doi.org/10.1021/acsami.5b00514
Dun, Chaochao, et al. "Layered Bi2Se3 nanoplate/polyvinylidene fluoride composite based n-type thermoelectric fabrics." ACS applied materials & interfaces vol. 7,13 (2015): 7054-9. doi: https://doi.org/10.1021/acsami.5b00514
Dun C, Hewitt CA, Huang H, Xu J, Montgomery DS, Nie W, Jiang Q, Carroll DL. Layered Bi2Se3 nanoplate/polyvinylidene fluoride composite based n-type thermoelectric fabrics. ACS Appl Mater Interfaces. 2015 Apr 08;7(13):7054-9. doi: 10.1021/acsami.5b00514. Epub 2015 Mar 27. PMID: 25798653.
Copy Download .nbib Format: NLM
The AMP-Dependent Protein Kinase (AMPK) Activator A-769662 Causes Arterial Relaxation by Reducing Cytosolic Free Calcium Independently of an Increase in AMPK Phosphorylation.

Frontiers in pharmacology

Huang Y, Smith CA, Chen G, Sharma B, Miner AS, Barbee RW, Ratz PH.
PMID: 29093683
Front Pharmacol. 2017 Oct 18;8:756. doi: 10.3389/fphar.2017.00756. eCollection 2017.

Although recent studies reveal that activation of the metabolic and Ca

Cite
Huang Y, Smith CA, Chen G, et al. The AMP-Dependent Protein Kinase (AMPK) Activator A-769662 Causes Arterial Relaxation by Reducing Cytosolic Free Calcium Independently of an Increase in AMPK Phosphorylation. Front Pharmacol. 2017;8:756doi: 10.3389/fphar.2017.00756.
Huang, Y., Smith, C. A., Chen, G., Sharma, B., Miner, A. S., Barbee, R. W., & Ratz, P. H. (2017). The AMP-Dependent Protein Kinase (AMPK) Activator A-769662 Causes Arterial Relaxation by Reducing Cytosolic Free Calcium Independently of an Increase in AMPK Phosphorylation. Frontiers in pharmacology, 8756. https://doi.org/10.3389/fphar.2017.00756
Huang, Yi, et al. "The AMP-Dependent Protein Kinase (AMPK) Activator A-769662 Causes Arterial Relaxation by Reducing Cytosolic Free Calcium Independently of an Increase in AMPK Phosphorylation." Frontiers in pharmacology vol. 8 (2017): 756. doi: https://doi.org/10.3389/fphar.2017.00756
Huang Y, Smith CA, Chen G, Sharma B, Miner AS, Barbee RW, Ratz PH. The AMP-Dependent Protein Kinase (AMPK) Activator A-769662 Causes Arterial Relaxation by Reducing Cytosolic Free Calcium Independently of an Increase in AMPK Phosphorylation. Front Pharmacol. 2017 Oct 18;8:756. doi: 10.3389/fphar.2017.00756. eCollection 2017. PMID: 29093683; PMCID: PMC5651270.
Copy Download .nbib Format: NLM
Effect of an herbal/botanical supplement on recovery from delayed onset muscle soreness: a randomized placebo-controlled trial.

Journal of the International Society of Sports Nutrition

Rynders CA, Weltman JY, Rynders SD, Patrie J, McKnight J, Katch FI, Hertel J, Weltman A.
PMID: 24966805
J Int Soc Sports Nutr. 2014 Jun 13;11:27. doi: 10.1186/1550-2783-11-27. eCollection 2014.

BACKGROUND: We examined the effects of a proprietary herbal/botanical supplement (StemSport, Stemtech, San Clemente, CA.) suggested to increase circulating stem cells, decrease inflammation, and attenuate exercise induced muscle damage on recovery from delayed onset muscle soreness (DOMS).METHODS: Sixteen subjects...

Cite
Rynders CA, Weltman JY, Rynders SD, et al. Effect of an herbal/botanical supplement on recovery from delayed onset muscle soreness: a randomized placebo-controlled trial. J Int Soc Sports Nutr. 2014;11:27doi: 10.1186/1550-2783-11-27.
Rynders, C. A., Weltman, J. Y., Rynders, S. D., Patrie, J., McKnight, J., Katch, F. I., Hertel, J., & Weltman, A. (2014). Effect of an herbal/botanical supplement on recovery from delayed onset muscle soreness: a randomized placebo-controlled trial. Journal of the International Society of Sports Nutrition, 1127. https://doi.org/10.1186/1550-2783-11-27
Rynders, Corey A, et al. "Effect of an herbal/botanical supplement on recovery from delayed onset muscle soreness: a randomized placebo-controlled trial." Journal of the International Society of Sports Nutrition vol. 11 (2014): 27. doi: https://doi.org/10.1186/1550-2783-11-27
Rynders CA, Weltman JY, Rynders SD, Patrie J, McKnight J, Katch FI, Hertel J, Weltman A. Effect of an herbal/botanical supplement on recovery from delayed onset muscle soreness: a randomized placebo-controlled trial. J Int Soc Sports Nutr. 2014 Jun 13;11:27. doi: 10.1186/1550-2783-11-27. eCollection 2014. PMID: 24966805; PMCID: PMC4071077.
Copy Download .nbib Format: NLM
Impact of Caregiving for Patients with Alzheimer's Disease and Dementia on Psychiatric and Clinical Comorbidities in Brazil.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Goren A, Novick D, Barros BR, Laks J, Dueñas H, Kahle-Wrobleski K.
PMID: 27200965
Value Health. 2014 Nov;17(7):A402. doi: 10.1016/j.jval.2014.08.921. Epub 2014 Oct 26.

No abstract available.

Cite
Goren A, Novick D, Barros BR, et al. Impact of Caregiving for Patients with Alzheimer's Disease and Dementia on Psychiatric and Clinical Comorbidities in Brazil. Value Health. 2014;17(7):A402doi: 10.1016/j.jval.2014.08.921.
Goren, A., Novick, D., Barros, B. R., Laks, J., Dueñas, H., & Kahle-Wrobleski, K. (2014). Impact of Caregiving for Patients with Alzheimer's Disease and Dementia on Psychiatric and Clinical Comorbidities in Brazil. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A402. https://doi.org/10.1016/j.jval.2014.08.921
Goren, A, et al. "Impact of Caregiving for Patients with Alzheimer's Disease and Dementia on Psychiatric and Clinical Comorbidities in Brazil." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A402. doi: https://doi.org/10.1016/j.jval.2014.08.921
Goren A, Novick D, Barros BR, Laks J, Dueñas H, Kahle-Wrobleski K. Impact of Caregiving for Patients with Alzheimer's Disease and Dementia on Psychiatric and Clinical Comorbidities in Brazil. Value Health. 2014 Nov;17(7):A402. doi: 10.1016/j.jval.2014.08.921. Epub 2014 Oct 26. PMID: 27200965.
Copy Download .nbib Format: NLM
Ovarian Torsion in the Third Trimester of Pregnancy Leading to Iatrogenic Preterm Delivery.

Case reports in obstetrics and gynecology

Vlachodimitropoulou Koumoutsea E, Gupta M, Hollingworth A, Gorry A.
PMID: 27066282
Case Rep Obstet Gynecol. 2016;2016:8426270. doi: 10.1155/2016/8426270. Epub 2016 Mar 15.

Ovarian torsion in the third trimester of pregnancy leading to a midline laparotomy and caesarean section for the delivery of a preterm baby is an uncommon event. As the woman is likely to present with nonspecific symptoms of lower...

Cite
Vlachodimitropoulou Koumoutsea E, Gupta M, Hollingworth A, et al. Ovarian Torsion in the Third Trimester of Pregnancy Leading to Iatrogenic Preterm Delivery. Case Rep Obstet Gynecol. 2016;2016:8426270doi: 10.1155/2016/8426270.
Vlachodimitropoulou Koumoutsea, E., Gupta, M., Hollingworth, A., & Gorry, A. (2016). Ovarian Torsion in the Third Trimester of Pregnancy Leading to Iatrogenic Preterm Delivery. Case reports in obstetrics and gynecology, 20168426270. https://doi.org/10.1155/2016/8426270
Vlachodimitropoulou Koumoutsea, Evangelia, et al. "Ovarian Torsion in the Third Trimester of Pregnancy Leading to Iatrogenic Preterm Delivery." Case reports in obstetrics and gynecology vol. 2016 (2016): 8426270. doi: https://doi.org/10.1155/2016/8426270
Vlachodimitropoulou Koumoutsea E, Gupta M, Hollingworth A, Gorry A. Ovarian Torsion in the Third Trimester of Pregnancy Leading to Iatrogenic Preterm Delivery. Case Rep Obstet Gynecol. 2016;2016:8426270. doi: 10.1155/2016/8426270. Epub 2016 Mar 15. PMID: 27066282; PMCID: PMC4811069.
Copy Download .nbib Format: NLM
Novel segmental proxy measures for estimating weight and height in healthy school children aged 11-18 years.

Clinical nutrition ESPEN

Carey A, McCarthy H, Gill J, Thompson A, McNulty H.
PMID: 28531548
Clin Nutr ESPEN. 2015 Oct;10(5):e211. doi: 10.1016/j.clnesp.2015.03.078. Epub 2015 Aug 28.

No abstract available.

Cite
Carey A, McCarthy H, Gill J, et al. Novel segmental proxy measures for estimating weight and height in healthy school children aged 11-18 years. Clin Nutr ESPEN. 2015;10(5):e211doi: 10.1016/j.clnesp.2015.03.078.
Carey, A., McCarthy, H., Gill, J., Thompson, A., & McNulty, H. (2015). Novel segmental proxy measures for estimating weight and height in healthy school children aged 11-18 years. Clinical nutrition ESPEN, 10(5), e211. https://doi.org/10.1016/j.clnesp.2015.03.078
Carey, A, et al. "Novel segmental proxy measures for estimating weight and height in healthy school children aged 11-18 years." Clinical nutrition ESPEN vol. 10,5 (2015): e211. doi: https://doi.org/10.1016/j.clnesp.2015.03.078
Carey A, McCarthy H, Gill J, Thompson A, McNulty H. Novel segmental proxy measures for estimating weight and height in healthy school children aged 11-18 years. Clin Nutr ESPEN. 2015 Oct;10(5):e211. doi: 10.1016/j.clnesp.2015.03.078. Epub 2015 Aug 28. PMID: 28531548.
Copy Download .nbib Format: NLM
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Case reports in oncology

Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C.
PMID: 27065848
Case Rep Oncol. 2016 Mar 10;9(1):164-70. doi: 10.1159/000444633. eCollection 2016.

Neuroendocrine tumors (NETs) are grouped together as a single class on the basis of histologic appearance, immunoreactivity for the neuroendocrine markers chromogranin A and synaptophysin, and potential secretion of hormones, neurotransmitters, neuromodulators and neuropeptides. Nevertheless, despite these common characteristics,...

Cite
Carter CA, Schmitz B, Peterson PG, et al. Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Rep Oncol. 2016;9(1):164-70doi: 10.1159/000444633.
Carter, C. A., Schmitz, B., Peterson, P. G., Quinn, M., Degesys, A., Jenkins, J., Oronsky, B., Scicinski, J., Caroen, S., Reid, T. R., Cabrales, P., & Brzezniak, C. (2016). Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case reports in oncology, 9(1), 164-70. https://doi.org/10.1159/000444633
Carter, Corey A, et al. "Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001." Case reports in oncology vol. 9,1 (2016): 164-70. doi: https://doi.org/10.1159/000444633
Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C. Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Rep Oncol. 2016 Mar 10;9(1):164-70. doi: 10.1159/000444633. eCollection 2016. PMID: 27065848; PMCID: PMC4821155.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 439 entries